AstraZeneca announced a major milestone with its investigational myasthenia gravis treatment gefurulimab clearing a Phase III trial, meeting all primary and secondary endpoints. The company highlighted that gefurulimab demonstrated a statistically significant and clinically meaningful improvement from baseline using the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, a validated measurement tool for symptoms of myasthenia gravis.
Analysts at William Blair provided insights on the significance of this achievement, comparing gefurulimab’s performance to a comparable approved daily treatment. Gefurulimab, a complement C5 inhibiting nanobody, is being tested in the Phase III PREVAIL trial in adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis, a debilitating autoimmune condition affecting communication between the brain and muscles. The potential competition in the market with the FDA-approved Zilbrysq and argenx’s Vyvgart adds an interesting dynamic to the landscape. AstraZeneca’s success with gefurulimab marks a significant advancement in the treatment of myasthenia gravis and sets the stage for further developments in the field.
Read more from biospace.com